Responsible Research Hospital Completes First On-line Adaptive Clinical Treatment with Manteia Mozi TPS Software
- Claire Chen
- Feb 2
- 2 min read
CAMPOBASSO, ITALY – In a move hailed by Italian media as an "epochal turning point," the Responsible Research Hospital (formerly Gemelli Molise) has officially launched clinical Online Adaptive Radiotherapy (oART). Unlike traditional approaches that rely on multi-million dollar hardware replacements, this milestone was achieved through the Manteia Mozi AI-driven software platform.
Strategic Vision: AI as a "Concrete Frontier"
For the hospital’s leadership, choosing a software-centric path was both a strategic and ethical decision. Stefano Petracca, Chairman of the Responsible Research Hospital, emphasized that Mozi represents the future of clinical responsibility:
"Mozi represents the concrete frontier of AI in radiotherapy. It is more than just a technical upgrade; it is a commitment to our patients. By providing higher precision and deep personalization through intelligence rather than just equipment, we are fulfilling our responsibility to offer the safest care possible."
Dr. Giovanni Guglielmucci, Medical Director, added that Mozi’s strength lies in its ability to streamline complexity: "To translate innovation into real patient benefits, you need robust clinical management. Mozi fits our workflow perfectly—it makes the complex adaptive process clear, controllable, and highly efficient."
The Software Revolution: Intelligence Over Equipment
Historically, Online ART required massive capital investment in proprietary hardware. Manteia Mozi disrupts this model by providing a vendor-independent software engine that brings "Radiotherapy 4.0" to existing treatment machines.
Dr. Savino Cilla, Head of Medical Physics, highlighted the shift: "Mozi allows for session-by-session adaptation through pure AI power. By capturing anatomical changes and recalculating the optimal plan in minutes via software, we have made 'see-and-treat' precision a daily clinical reality."
Eliminating the "Average Patient" Model
The core of this breakthrough lies in the software’s ability to move past the "average patient" assumption. Dr. Francesco Deodato, Head of Radiation Oncology, noted: "With Mozi, we are no longer bound by static protocols. The software allows us to treat the patient based on their anatomy today, not as they were weeks ago."
Setting a New Benchmark
The successful clinical rollout at Responsible Research Hospital confirms Manteia Mozi as a "core engine" for European innovation. This landmark case proves that the future of oncology is being written in intelligent software, making life-saving adaptive therapy more accessible and flexible for top-tier institutions worldwide.
Resources: